Effective protection against hip fracture during cortisone treatment (Update)

July 11, 2017
Mattias Lorentzon, M.D., Ph.D. is responsible for the study on hip fractures during cortisone medication. Credit: Elin Lindstrom Claessen/University of Gothenburg

There is effective protection against hip fracture for the many elderly people whose skeleton is declining in strength, as a side effect of cortisone treatment. If patients receive the osteoporosis medication alendronate, it reduces the risk of hip fracture by 65 percent, as a study published in The Journal of the American Medical Association (JAMA) reveals.

"The low number of people who receive this protective treatment is often due to a lack of knowledge and procedures in this area within the healthcare system," says Mattias Lorentzon, a professor of geriatric medicine at the Sahlgrenska Academy's Institute of Medicine, and a senior physician at Sahlgrenska University Hospital.

Hip fractures usually affect older people and often lead to disability, a worse quality of life and premature death. For many aged 80 or over, the combination of extensive surgery, immobility and long hospital stays, with a risk of infection, blood clots and confusion, is simply too much.

Cortisone treatment to counteract inflammation conditions such as rheumatoid or muscular arthritis, meanwhile, doubles the risk of hip fracture. This latest study has revealed, however, that just one in four patients treated with cortisone receive the osteoporosis medication alendronate.

Significant Reduction of Risk

The aforementioned study was made possible by interlinking several registers in Sweden, namely Senior Alert, the patient register, the drug register, the cause of death register and the population register.

From a base group of over 400,000 elderly patients, 1802 were prescribed alendronate after starting treatment with the cortisone preparation prednisolone in tablet form. They had been taking the drug for at least three months, at a dosage of at least five milligrams per day.

Kristian Axelsson, M.D., M.Sc. is one of the authors behind the study about hip fractures during cortisone medication. Credit: Skaraborgs Sjukhus

The group with matched controls, which also consisted of 1802 people, took prednisolone tablets, but did not receive the protective alendronate treatment.

Of those who took cortisone tablets, but did not receive protective treatment, 4.1 percent had broken their hip after around 15 months (1.3 years). In the group that also received alendronate (the protective substance), the equivalent figure was 1.5 percent. This represented a significant reduction in the risk, i.e. 65 percent less, covering other fractures too.

"If a patient receives the protective treatment, the risk of suffering a new fracture, and in particular the new hip fractures that we are really keen to prevent, reduces dramatically," says Kristian Axelsson, co-author and doctoral candidate, who also works as a resident physician in the orthopedics department at Skaraborgs Hospital.

"The number of patients receiving the treatment is quite low at present, but we are hoping this study will mean more prednisolone patients will receive the fracture-preventing treatment," he continues.

Really Helps to Avoid It

Most hip fractures occur in older women. The average age in the study was around 80 years, and seven out of ten of the patients were women. There was no increased risk of side effects linked to the alendronate treatment, and for Mattias Lorentzon, it is clear what the study has achieved.

"This drug costs around SEK 200 per person per year, which is nothing really, thanks to the fact that it's a generic drug for which no patent is outstanding. It's unlikely any company will invest large amounts of money on a randomized trial to investigate whether it prevents hip fractures in cortisone patients. It perhaps wouldn't be too ethical either, because there is already indirect evidence that it should work," he tells us.

"That's why we wanted to look at the question at issue as part of a major retrospective observational study. The data we now have really supports the argument that it provides effective protection against hip fracture, one of the most costly complaints within the Swedish healthcare system, and something that many people of this age die from. It really helps if you can avoid it," he concludes.

Explore further: Study looks at predicting fracture risk after women stop bisphosphonate therapy

More information: Kristian F. Axelsson et al, Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone, JAMA (2017). jamanetwork.com/journals/jama/ … .1001/jama.2017.8040

Related Stories

Study looks at predicting fracture risk after women stop bisphosphonate therapy

May 5, 2014
Age and testing of hip bone mineral density (BDM) when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures over the next five years.

Good news for people with osteoporosis

July 25, 2016
When it comes to your bone health, the benefits of alendronate outweigh the risks, Associate Professor Daniel Prieto-Alhambra from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences tells Jo ...

Alendronate reduces adjacent-level vertebral fractures

December 30, 2013
(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue of Spine.

Findings support bisphosphonate use in men with osteoporosis

November 16, 2016
(HealthDay)—Bisphosphonates reduce the risk of vertebral, and possibly nonvertebral, fractures for men with osteoporosis, according to a review and meta-analysis published online Nov. 7 in the Journal of the American Geriatrics ...

Bone mineral density tx can be effective for young CF patients

June 4, 2013
(HealthDay)—For children and young adults with cystic fibrosis, adequate calcium intake plus calcifediol can improve bone mineral density, while alendronate can increase bone mineral density for some non-responders, according ...

Recommended for you

Superbug's spread to Vietnam threatens malaria control

September 21, 2017
A highly drug resistant malaria 'superbug' from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine—Vietnam's national first-line malaria treatment, ...

Individualized diets for irritable bowel syndrome better than placebo

September 21, 2017
Patients with irritable bowel syndrome who follow individualized diets based on food sensitivity testing experience fewer symptoms, say Yale researchers. Their study is among the first to provide scientific evidence for this ...

A dose of 'wait-and-see' reduces unnecessary antibiotic use

September 21, 2017
Asking patients to take a 'wait-and-see' approach before having their antibiotic prescriptions filled significantly reduces unnecessary use, a University of Queensland study has shown.

Investigators may unlock mystery of how staph cells dodge the body's immune system

September 21, 2017
For years, medical investigators have tried and failed to develop vaccines for a type of staph bacteria associated with the deadly superbug MRSA. But a new study by Cedars-Sinai investigators shows how staph cells evade the ...

Groundbreaking investigative effort identifies gonorrhea vaccine candidates

September 19, 2017
Researchers at Oregon State University have identified a pair of proteins that show promise as the basis for a gonorrhea vaccine.

Snail fever progression linked to nitric oxide production

September 14, 2017
Bilharzia, caused by a parasitic worm found in freshwater called Schistosoma, infects around 200 million people globally and its advance can lead to death, especially in children in developing countries.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.